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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S209Purpose: Non-steroidal anti-inﬂammatory agents (NSAIDs) are com-
monly used to manage symptoms in patients with knee osteoarthritis
(OA). While randomized controlled trials have demonstrated efﬁcacy,
real world effectiveness of these agents in long term studies is lacking.
This study sought to estimate the effectiveness of NSAIDs on symptom
management over 4 years among persons with radiographically con-
ﬁrmed OA. Marginal structural models, which take into consideration
the likely dual role of indices of disease severity as confounders and
intermediary variables, were compared to standard repeated-measure
analyses.
Methods: We identiﬁed NSAID naïve participants with radiographic
knee OA in the Osteoarthritis Initiative. Participants were evaluated
over 4 years. NSAID users included those reporting any use of pre-
scription medication use (i.e., either regular use or as-needed use) at
each assessment. Outcome measures included WOMAC Pain, Stiffness
and Physical Function. Beta coefﬁcients derived from marginal struc-
tural models and generalized estimating equation models represented
the average change in outcomemeasures attributed to long term NSAID
use. Minimally important clinical differences were a priori set as at least
1.2 for pain, 0.5 for stiffness, and 4.1 for function.
Results: Persons with radiographically conﬁrmed OA with long term
reports of prescription NSAIDS use experienced improvements in
WOMAC Pain: -0.99 (95% Conﬁdence Interval (CI): -2.38 to 0.4);
WOMAC Stiffness: -0.64 (95% CI: -1.52 to 0.24); and WOMAC Function:
-5.29 (95% CI: -9.7 to -0.89). In contrast, the analysis with generalized
estimating equations yields an estimate of -0.03, -0.08 and 0.07 for
difference in Pain, Stiffness and Function, respectively.
Conclusions: When evaluated using marginal structural models, long
term use of NSAIDs showed a modest trend towards relieving symp-
toms and a clinically signiﬁcant improvement in function in patients
with radiographically conﬁrmed OA, whereas a standard regression
models didn’t show such beneﬁts. Studies on the treatment of OA using
non-experimental data should consider using marginal structural
models when evaluating the overall treatment effect from a time-
varying treatment.
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Purpose: Although Total Hip Replacement (THR) is a successful surgical
intervention, there are a minority of patients who do not achieve
clinically meaningful improvement or whose symptoms get worse
following surgery. The aim of this study was to develop a clinical risk
prediction tool to predict patient reported outcomes following primary
hip replacement surgery.
Methods: We obtained data on two prospective cohorts of patients
receiving primary THR for osteoarthritis: Exeter Primary Outcomes
Study (n ¼ 1247); EUROHIP (n ¼ 845). The primary outcome was the
Oxford Hip Score (OHS). Combining data from two large prospective
cohort studies allowed us to take account of a wide and comprehensive
range of both traditional and novel risk factors, including patient,
radiographic and surgical predictors. Linear regression modelling was
used to identify predictors of outcome. For internal validationwe used a
combination of multiple imputation and bootstrapping with backward
selection. Performance of the predictive model was assessed in terms of
calibration and discrimination.
Results: Of the radiographic variables pattern of OA was an important
determinant of outcome. Those with superomedial, medial or concen-
tric disease had worse outcomes than patients with a superolateral
pattern of OA or no reduction in joint space. Arthritis in other joints, and
previous surgery on other joints, were associated with worse outcomes.For surgical variables, a posterior surgical approach, and larger femoral
component offset had better outcomes. For patient factors, worse pre-
operative pain/function, increasing age when over age 75, increasing
BMI, lower levels of educational attainment and those with worse pre-
operative SF36 mental health scores, also had worse outcomes.
These factors were operationalized into a clinical risk prediction tool.
Calibration of the predicted 12-month post-operative OHS, and abso-
lute change in OHS was good. The model showed good discriminatory
ability with a bias corrected R-squared of 23.1%. We tested the ability of
the model to identify patients with the worst possible outcomes fol-
lowing THR (deﬁned as a change in OHS < 5-points of whom 89 (4.25%)
patients met this criterion). Performance of the tool to identify patients
with the worst outcomes was good (C-statistic 0.77 95%CI (0.72 to
0.82)).
Conclusions: We have developed a clinical risk prediction tool that
would provide information on the likely outcomes of hip replacement
surgery. Following hip replacement the majority of patients do very
well, and only a minority will not achieve clinically meaningful symp-
tomatic change in OHS. The clinical tool performed well in terms of its
calibration and discriminatory ability, and identiﬁcation of those
patients with the worst possible outcomes was good. The tool provides
individualised risk prediction and allows patients to understand their
expected outcomes of surgery – it has the potential to guide patient-
clinician decision-making. It will now undergo external validation in a
new prospective cohort of patients.
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Purpose: (1) The aim of the study was to systematically summarize the
literature from March 2005 to January 2013 on the course of physical
functioning and pain in patients with OA of the knee or hip and (2) to
provide an overview of prognostic factors of physical functioning and
future pain for these patients.
Methods: A search was conducted in PubMed, CINAHL, Embase and
Psych-INFO in January 2013. Eligible studies were prospective cohort
studies (minimum follow up was  6 months) that included partic-
ipants with knee or hip OA diagnosed with radiographically and/or
Table 1
OA-Related Mean Cumulative One-Year Costs by Joint Location, Age, and
Comorbidity
Subgroup Total
Medical*
Inpatient Outpatient Physical or
Occupational
Therapy
Pharmacy
Overall $8,644 $3,533 $4,921 $265 $2,179
Joint location
Knee $9,466 $4,178 $5,093 $292 $2,086
Hip $12,478 $7,473 $4,818 $295 $2,047
Hand $6,705 $1,505 $5,004 $221 $2,256
Age group, y
18–44 $10,857 $3,398 $7,070 $440 $1,794
45–64 $12,799 $5,400 $7,144 $395 $2,258
65y $3,510 $1,429 $2,002 $84 $2,156
Comorbidity
Hypertension $8,917 $3,855 $4,857 $232 $2,519
CVD $10,844 $4,993 $5,575 $157 $3,150
Diabetes $10,815 $4,709 $5,859 $242 $3,358
CVD ¼ cardiovascular disease; OA ¼ osteoarthritis.
*Total medical costs are equal to the sum of inpatient, outpatient, and emergency
room costs, excluding physical or occupational therapy and pharmacy costs.
yCosts for patients 65 are underestimated because payments observed here are
supplements to Medicare.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S210clinically diagnosed knee or hip OA, or participants with knee or hip
pain for more than one month who were likely to have OA. Outcome
measures were measurements that evaluated physical functioning and
pain. The included articles were assessed for bias and the results were
summarized according to best evidence synthesis.
Results: Of the 9068 studies that were found, 27 articles were included.
In patients with knee OA, the average course of physical functioning
varied between studies (inconsistent evidence). The samewas found for
the average course of knee pain in studies with a follow up period
shorter than three years. Only one study examined the course of pain
over a longer period, and found an improvement in pain over six years
(weak evidence). In addition, in patients with hip OA the average course
of physical functioning in studies with a follow up period shorter than
three years was found to be stable (strong evidence). Because only one
study examined the course of physical functioning over a period longer
than three years, weak evidence was found for a stable course over 5
years. No publications were found that examined the course of pain in
patients with hip OA. With regard to prognostic factors, in patients with
knee OA strong evidence was found for various prognostic factors for
future deterioration in physical functioning i.e. older age, a low to
middle education level, higher body mass index, high morbidity count,
use of pain medication, greater difﬁculties with physical functioning at
baseline, lower knee extension strength, higher pain intensity, patella-
femoral joint compression, lower walking ability, poor mental health
and a low vitality. With regard to predictors for future knee pain, a
longer symptom duration, bilateral knee symptoms and a higher level
of pain at baseline were found to predict future pain in patients with
knee OA (strong evidence). In hip OA strong evidence was found that a
high morbidity count and a low vitality increase the likelihood of
deterioration of physical functioning. No publications were found on
prognostic factors for future pain.
Conclusion: The average course of physical functioning and pain in
patients with knee OAwas found to be variable between studies. In hip
OA, the long-term course of physical functioning was found to be stable.
In comparison to a previous review stronger evidence was found for a
number of variables to be prognostic factors of physical functioning and
pain, including demographic factors, clinical factors, knee character-
istics and psychosocial factors. Knowledge on prognostic factors can be
used to inform patients on the likely course of their condition and to
adapt treatment according to the prognosis. Although many studies
have been carried out recently, more studies with a longitudinal design
are warranted, especially in patients with hip OA.
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Purpose: Osteoarthritis (OA) is the most common form of arthritis and
the leading cause of working age disabilities. Over 27 million US adults
have clinical OA, and different types of burdens exist based on the
disease stages and locations. The burden of OA by joint location, age, or
comorbidity has not been well studied. The objective of this study was
to assess the excess health care resource use and costs attributable to
OA by joint location, age, and comorbidity in a privately insured
population.
Methods: 428,084 OA patients aged18 were selected from a US-based
employer claims database (1999–2011). Controls were selected from the
same database by matching OA patients 1:1 by age, gender, index date,
and follow-up time to patients who never had OA in their claims his-
tories. Descriptive analyses were used to compare baseline character-
istics and study period medical resource use and costs, inﬂated to 2011
US dollars using annual medical Consumer Price Index data (Bureau of
Labor Statistics). Statistical comparisons were made using McNemar’s
test for categorical variables and the Wilcoxon signed-rank test for
continuous variables.
Results: Among all the OA patients studied,181,379 had a primary claim
of knee OA; 48,617 had hip OA; 29,340 had hand OA; and 30,549 had
spine OA. The average age of OA patients was 63 years and 59% were
female. At baseline, OA patients tended to have a greater comorbidity
burden than controls (P< 0.001). The occurrence of the 4most common
comorbidities between the OA group and controls were hypertension
(45% vs 30%, respectively), cardiovascular disease (14% vs 8%,respectively), diabetes (16% vs 10%, respectively), and depression (8% vs
4%, respectively). OA patients aged 18 incurred total annual medical
costs of $8,644 vs $2,273 in controls (P < 0.001). 20% of all OA patients
had at least 1 primary joint arthroplasty, 1% had a revision joint
arthroplasty, and 2% had arthrodesis. The cost per surgery ranged from
$16,000 to $25,000. On average, a hip arthroplasty cost $18,425 and a
knee arthroplasty cost $17,433. Annual pharmacy cost was $2,179 for OA
patients and $1,096 for controls. OA-related health care costs are
summarized by joint locations, age, and comorbidity in Table 1.Con-Conclusions: Patients with OA incur greater medical and pharmacy
costs than those without OA. The burden of OA varies substantially by
joint location. Surgical procedures are the most signiﬁcant cost among
all categories, and therefore is also one of the main drivers of the total
cost. In contrast, pharmacy costs are rather small due to no disease-
modifying OA drug (DMOAD) available. Hand OA had lower costs than
knee and hip OA due to lack of DMOADs and effective surgery. In
summary, OA presents a great disease and economic burden. The cur-
rent treatment options are limited to generic symptom-modifying
drugs and late-stage surgical management of the disease, but the latter
is only available for certain joints.
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Purpose: Osteoarthritis (OA) produces pain and mobility limitations
which require intensive primary care management. Once the disease
reaches an advanced stage, total hip replacements (THRs) are very
effective at improving patients’ health and reducing demand for pri-
mary care resources. The costs of managing OA before surgery, however,
have not been thoroughly explored leading to most assessments of
THRs to exclude these costs from economic models. We aimed to
describe the use of primary care resources attributable to OA in the UK
and to estimate the costs borne by the NHS for these services.
Methods: We used data from the General Practice Research Database
(GPRD, now CPRD) of all patients with a primary THR before 31
December 2006 who were 45 years of age or older at the time of
operation. The data set included the clinical history of up to ﬁve controls
for each THR case. Controls had no record of hip arthroplasty, OA or
arthritis, and were matched to cases by GP practice, gender and age.
Data included consultations with GPs, nurses, consultants and allied
health professionals (AHP) as well as prescription of selected 25 drugs
grouped into categories as NSAIDs, opioid and non-opioid analgesics,
